Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells $619,298.13 in Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 19,679 shares of the stock in a transaction dated Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total value of $619,298.13. Following the completion of the sale, the insider owned 25,249 shares of the company’s stock, valued at approximately $794,586.03. This trade represents a 43.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

David Krempa also recently made the following trade(s):

• On Friday, May 22nd, David Krempa sold 42,797 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83.
• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $31.49, for a total value of $1,181,630.76.

Eton Pharmaceuticals Trading Down 4.4%

Eton Pharmaceuticals stock opened at $30.45 on Friday. The stock has a 50-day moving average of $27.08 and a two-hundred day moving average of $20.21. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. Eton Pharmaceuticals, Inc. has a one year low of $13.09 and a one year high of $35.66. The stock has a market cap of $834.09 million, a PE ratio of -434.94 and a beta of 0.82.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. The business had revenue of $24.27 million during the quarter, compared to analysts’ expectations of $22.31 million. On average, research analysts anticipate that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Craig Hallum raised their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, March 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Tuesday, April 21st. Zacks Research cut Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 17th. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 21st. Finally, HC Wainwright raised their price objective on Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $41.00.

Institutional Trading of Eton Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the company. Bank of America Corp DE boosted its stake in shares of Eton Pharmaceuticals by 37.8% in the first quarter. Bank of America Corp DE now owns 144,367 shares of the company’s stock worth $3,563,000 after acquiring an additional 39,571 shares during the last quarter. EcoR1 Capital LLC boosted its stake in shares of Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock worth $53,603,000 after acquiring an additional 141,394 shares during the last quarter. Aristides Capital LLC boosted its stake in shares of Eton Pharmaceuticals by 15.2% in the first quarter. Aristides Capital LLC now owns 186,041 shares of the company’s stock worth $4,591,000 after acquiring an additional 24,605 shares during the last quarter. Bank of Nova Scotia acquired a new stake in shares of Eton Pharmaceuticals in the first quarter worth approximately $365,000. Finally, Sei Investments Co. acquired a new stake in shares of Eton Pharmaceuticals in the first quarter worth approximately $1,432,000. 27.86% of the stock is owned by institutional investors and hedge funds.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.